Akèy › Kansè Poumon ki pa ti selil › Connecticut

Etid klinik pou Kansè Poumon ki pa ti selil nan Connecticut

55 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan Connecticut.

Vil nan Connecticut

Tèks ofisyèl etid la (Anglè)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Smilow Cancer Hospital-Derby Care Center, Derby
Smilow Cancer Hospital Care Center-Fairfield, Fairfield
Smilow Cancer Hospital Care Center at Greenwich, Greenwich
ak 9 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Yale University School of Medicine ( Site 0201), New Haven
Eastern CT Hematology & Oncology Associates ( Site 0202), Norwich

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06623422

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Eastern Connecticut Hematology and Oncology Associates, Norwich

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06472245

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Yale Cancer Center, New Haven

Ap rekriteFaz 1/2

Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #62, New Haven

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Smilow Cancer Center at Yale-New Haven ( Site 3253), New Haven

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07513376

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Yale Cancer Center, New Haven

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06172478

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Smilow Cancer Hospital - Yale New Haven Health, New Haven
Yale - New Haven Hospital - Yale Cancer Center, New Haven
Smilow Cancer Hospital Phase 1 Unit, New Haven
ak 1 plis

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07090499

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

University of Connecticut Health Center ( Site 0130), Farmington
Stamford Hospital ( Site 0126), Stamford

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Hartford HealthCare - Avon, Avon
Hartford Hospital, Hartford
Hartford HealthCare - Manchester, Manchester
ak 2 plis

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Yale Cancer Center, New Haven

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07578571

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Yale University, Smillow Cancer Center, New Haven

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06881784

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Stamford Hospital ( Site 0083), Stamford

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312137

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Yale New Haven Hospital Yale Cancer Center, New Haven

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667076

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Yale University, New Haven

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667908

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Hartford Hospital (HH), Hartford

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06890598

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Kivu Trial Site, New Have

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07229313

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, New Haven

Ap rekriteFaz 2

Laj 18 a 95 · Tout sèks · Mizajou Sep 23, 2026 · NCT05061550

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Yale New Haven Hospital /ID# 271584, New Haven

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06568939

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Yale University, Yale Cancer Center, New Haven

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, West Haven

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06692738

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Yale Cancer Center, New Haven

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07349537

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Yale University School of Medicine - Yale Cancer Center, New Haven

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Eastern Connecticut Hematology and Oncology Associates, Norwich

Ap rekriteFaz 2/3

Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Yale Cancer Center, New Haven

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06303505

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Yale Cancer Center, New Haven

Ap rekriteFaz 2

Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT04302025

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

Yale Cancer Center, New Haven

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07166601

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Hartford Hospital, Hartford

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06793215

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Stamford Hospital ( Site 0136), Stamford

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06345729

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Yale University School of Medicine, New Haven

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Yale Cancer Center, New Haven

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT05789082

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Yale Cancer Center, New Haven

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07361562

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

Yale Cancer Center, New Haven
Norwalk Hospital, Norwalk

Ap rekriteFaz 1

Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06343402

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Hartford Healthcare, Hartford
Yale University, New Haven

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07070232

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Research Site, New Haven

Ap rekriteFaz 3

Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06350097

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Yale University - Cancer Center, New Haven

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06706076

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Yale University, New Haven

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07111520

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Eastern Connecticut Hematology and Oncology Associates, Norwich

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT07397338

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Yale New Haven Hospital, Yale Cancer Center, New Haven

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Jul 21, 2026 · NCT05098132

Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

Smilow Cancer Hospital Care Center at Greenwich, Greenwich
Smilow Cancer Hospital Care Center - Guilford, Guilford
Smilow Cancer Hospital - Hamden Care Center, Hamden
ak 3 plis

Ap rekriteFaz 1/2

Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT04210492

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.